The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies.
N. Houede
No relevant relationships to disclose
S. J. Faivre
Consultant or Advisory Role - Amgen
Honoraria - Bayer; Merck Serono; Pfizer
A. Awada
No relevant relationships to disclose
E. Raymond
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Bayer; Novartis; Pfizer
A. Italiano
No relevant relationships to disclose
T. Besse-Hammer
No relevant relationships to disclose
M. Donica
Employment or Leadership Position - Merck Serono
N. Rejeb
Employment or Leadership Position - Merck Serono
C. Luepfert
Employment or Leadership Position - Merck KGaA
S. Ongarello
Employment or Leadership Position - Merck Serono
Research Funding - Merck Serono
J. Delord
Expert Testimony - Roche